2Lassen M R, Ageno W, Borris L C, et al..Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med, 2008, 358(26):2776-2786.
3Turpie A, BauerK, Davidson B, et al. Comparison of 6varoxa- ban-an oral, direct factor Xa inhibitor-and subcutaneous enoxa- parin lbr thromboprophylaxis after total knee replacement[R]. European Federation of National Associations of Orthopaedics and Traumatology.Annual MeetinR. 2008-05-29. France. Abstract F85.
4ROEHRIG S, STRAUB A, POHLMANN J. Discovery of the novel antithrombotic agent 5 -chloro-N- ( │( 5 S ) -2-ox0-3 - [ 4- ( 3 -oxomorpholin-4-yl) phenyl ] -1,3-oxazolidin-5-yl │ methyl ) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor[ J]. J Med Chem,2005,48 ( 19 ) :5900 - 5908.
5DAURE EW, FUJIKAWA K, KISIEL W. The coagulation cascude: Initiation, maintenance and regulation [ J ]. Biochemistry, 1991,30(43) :10363 - 10370.
6WEINZ C, BUETEHORN U,DAEHLER HP, et al. Pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in rats and dogs [ J ]. Xenobiotica, 2005,35 ( 9 ) : 891 -910
7KUBITZA D, BECKA M, ZUEHLSDOR M, et al. Effect of Food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban) , an oral, direct factor Xa inhibitor, in healthy subjects [ J ]. J Clin Pharm, 2006,46 ( 6 ) : 549 - 558.
8LASSEN MR, TUPRPIE AG, ROSENCHER N, et al. Rivaroxaban an oral, direct factor Xa inhibitor for thromboprophylaxis after totalknee arthroplasty: The RECORD3 Trial. (Abstract No.308). American Society of Hematology. 49th Annual Meeting. Atlanta. December 2007 [ EB/OL]. [ 2007 - 11 - 16 ]. http:// www. abstracts2view. com/hem07/view. php? nu = HEM07L1-2447.
9Pivotal phase III data showed rivaroxaban was statistically superior to enoxaparin in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. NewYork: BusinessWire[ EB/OL]. [ 2007 - 12 -08 ]. http ://proquest. umi. com/ pqdweb? did = 1395271941&sid = 1&Fmt = 7&clientld = 26489&RQT = 309&VName = PQD.
10HARRY BR, ANTHONIE LWA, MARTIN PH. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein_DVT Dose-Ranging Study [ J ]. Blood, 2008, 6 ( 112 ) :2242 - 2247.
3Erikssona BI, Rosencherb N, Friedman R J, et al. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthmplasty[J]. Thromb Res,2012,130(2) :201-206.
